Sex, intimacy and Parkinson’s disease: an expert guide
Health & Fitness
Author: Sophie BatesPublished: 19 May 2022
Prep: Cook: Serves:
We round up our four-part series on sex, intimacy and Parkinson’s, in which sex therapist, Gila Bronner, and nurse consultant, Orna Moore, share their expert advice – from practical tips on how to encourage intimacy in a relationship post-diagnosis to the importance of seeking professional help
1. Intimacy, sexuality and Parkinson’s
In the first part of the series, Gila and Orna discuss the importance of intimacy, and give a four-step, practical guide on ways to improve closeness in a relationship.
Intimacy, they explain, is an area that “frequently goes unnoticed and un-discussed”. The two experts recommend spending quality time with your partner, ensuring you both have moments alone to relax, committing to intimate time without the pressure to move on to sex, and sexual time.
“Couples need these four elements, even if some time passes without realising all four of them. It is important to invest in intimacy in a relationship.”
Gila and Orna emphasise that people with Parkinson’s may not realise that their condition is the cause of their sexual dysfunction, which is why it is important to talk about any issues with medical professionals – and for healthcare professionals to encourage this discussion.
“A loving relationship includes encouragement of intimacy, sensuality, companionship, and friendship, as well as continued knowledge and understanding about the effects that one’s health conditions, medications, and treatment have on sexuality and functioning.”
Gila and Orna share ways to ensure the wellbeing of both partners, such as respecting each other’s needs, having personal time away from one another, sleeping in separate beds if sleep is being disrupted, maintaining intimacy even if it’s not sexual, having strong communication and making small, thoughtful gestures that the other will appreciate.
“Spouses and care-partners frequently face contradictory roles,” they explain. “On one hand, as intimate partners, they may have their own needs for intimacy and sexual activity. On the other hand, they are required to function as caregivers who cope with the implications of a chronic progressive illness.”
In the final part of the series, Gila and Orna discuss coping with disturbed sexual function – one of the most common non-motor symptoms in people with young onset Parkinson’s – and share the difficulties many face of sustaining a sex life due to lack of time and other priorities.
“Young people with Parkinson’s experience the disease differently. They are coping with its various symptoms while also being in the middle of life challenges.”
They say openness is crucial to sustaining a healthy sexual relationship. To tackle any issues, they advise seeking professional help when necessary, being honest with one another, and being open with children about the effects of Parkinson’s.
Orna Moore is a nurse consultant, working with families with neurodegenerative diseases. She works at the Department of Neurology, Tel Aviv Medical Center, Israel.
Gila Bronner is a sex therapist specialising in sexual rehabilitation. She is director of the Sex Therapy Service at the Sexual Medicine Center, Tel Aviv, and a sex therapist at the Institute of Movement Disorders, Sheba Medical Center, Israel.
Tune into our love-themed podcast this Valentine’s Day
Two guests on dating, relationships, sex and Parkinson’s disease
6 hours ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”